ALK inhibitor

The FDA ( U.S. Food and Drug Administration ) has approved Xadago ( Safinamide ) tablets as an add-on treatment...


Modern therapy for multiple myeloma including generations of Thalidomide analogues, proteasome inhibitors and alkylating agents has substantially improved the survival...


The FDA ( Food and Drug Administration ) has found that type 2 diabetes medicines containing Saxagliptin and Alogliptin may...


A promising approach to neurotherapeutics involves activating the nuclear-factor-E2-related factor 2 ( Nrf2 ) / antioxidant response element signaling, which...


The FDA ( Food and Drug Administration ) has approved the Repatha ( Evolocumab ) Pushtronex system ( on-body infusor...


A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with Panitumumab plus Vemurafenib. Pre-existing...


Alectinib ( Alecensa ), an oral anaplastic lymphoma kinase ( ALK ) inhibitor, has reduced the risk of disease worsening...


Data were reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer ( WCLC )...


FDA ( Food and Drug Administration ) has strengthened the warning for the type 2 diabetes medicine Canagliflozin ( Invokana,...


Merck, known as MSD outside the United States and Canada, has announced new study findings investigating the use of Keytruda...


The FDA ( Food and Drug Administration ) has approved a new second-generation lung cancer treatment that can help many...


Mutations in the ALK gene were identified in the tumors of two leukemia patients, and laboratory studies indicated that leukemias...


Alectinib ( Alecensa ) is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase ( ALK...


Results from two pivotal studies ( NP28673 and NP28761 ) have showen Alectinib, an oral investigational anaplastic lymphoma kinase inhibitor...


Lung cancer is the number one cause of cancer mortality globally and has an estimated incidence of 1.3 million new...


The FDA ( Food and Drug Administration ) has granted Breakthrough Therapy Designation to Keytruda ( Pembrolizumab ), an anti-PD-1...


Serum Alkaline phosphatase ( ALP ) & phosphate are considered to be indicators of vascular calcification. Link between bone metabolism,...


Data of the first phase IIIb/IV study, AMBITION, were presented at the ERS International Congress 2014. The study has investigated...


The European Commission has granted marketing authorization for Zydelig ( Idelalisib ), 150 mg tablets, a first-in-class oral treatment for...


In 2013 American Society of Hematology ( ASH ) Annual Meeting data on several compounds in development for the treatment...